Insektengiftallergie

Prof. Dr. med. Tilo Biedermann

Literatur

• 1 Przybilla B, Rueff F, Fuchs T. et al . Insektengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI).  Allergo J. 2004;  13 186-190
• 2 Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes.  Lancet. 1977;  1 466-469
• 3 Wölbing F, Fischer J, Biedermann T. Ko-Faktoren der Anaphylaxie.  Allergo J. 2008;  17 563-568
• 4 Biedermann T, Schöpf P, Rueff F. et al . Anstrengungsinduzierte Anaphylaxie auf Rind- und Schweinefleisch.  Dtsch Med Wochenschr. 1999;  124 456-458
• 5 Simons F E, Frew A J, Ansotegui I J. et al . Risk assessment in anaphylaxis: current and future approaches.  J Allergy Clin Immunol. 2007;  120 (1 Suppl) S2-S24
• 6 Biedermann T, Hartmann K, Sing A. et al . Hypersensitivity to non-steroidal anti-inflammatory drugs and chronic urticaria cured by treatment of Blastocystis hominis infection.  Br J Dermatol. 2002;  146 1113-1114
• 7 Mauss V. Bionomie und Abwehrverhalten der in Deutschland vorkommenden allergologisch bedeutsamen Bienen und Faltenwespen.  Hautarzt. 2008;  59 184-193
• 8 King T P, Spangfort M D. Structure and biology of stinging insect venom allergens.  Int Arch Allergy Immunol. 2000;  123 99-106
• 9 Egner W, Ward C, Brown D L. et al . The frequency and clinical significance of specific IgE to both wasp (Vespula) and honey-bee (Apis) venoms in the same patient.  Clin Exp Allergy. 1998;  28 26-34
• 10 Jappe U, Raulf-Heimsoth M, Hoffmann M. et al . In vitro hymenoptera venom allergy diagnosis: improved by screening for cross-reactive carbohydrate determinants and reciprocal inhibition.  Allergy. 2006;  61 1220-1229
• 11 Hemmer W, Focke M, Kolarich D. et al . Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy.  J Allergy Clin Immunol. 2001;  108 1045-1052
• 12 Mari A. IgE to cross-reactive carbohydrate determinants: analysis of the distribution and appraisal of the in vivo and in vitro reactivity.  Int Arch Allergy Immunol. 2002;  129 286-295
• 13 Hemmer W. Kreuzreaktivität auf Bienen- und Wespengift.  Hautarzt. 2008;  59 194-199
• 14 Biedermann T, Rueff F, Sander C. et al . Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels.  Br J Dermatol. 1999;  141 1110-1112
• 15 Przybilla B, Müller U, Jarisch R. et al . Erhöhte basale Serumtryptasekonzentration oder Mastozytose als Risikofaktor der Hymenopterengiftallergie. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAI).  Allergo J. 2004;  13 440-442
• 16 Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology . The diagnosis and management of anaphylaxis: an updated practice parameter.  J Allergy Clin Immunol. 2005;  115 (3 Suppl 2) S483-S523
• 17 Ranft A, Kochs E F. Treatment of anaphylactic reactions: a review of guidelines and recommendations.  Anasthesiol Intensivmed Notfallmed Schmerzther. 2004;  39 2-9
• 18 Tryba M, Ahnefeld F W, Barth J. et al . Akuttherapie anaphylaktoider Reaktionen. Ergebnisse einer interdisziplinären Konsensuskonferenz.  Allergo J. 1994;  3 211-224
• 19 Ring J, Brockow K, Duda D. et al . Akuttherapie anaphylaktischer Reaktionen.  Allergo J. 2007;  16 420-434
• 20 Berner D, Fischer J, Biedermann T. Der Notfall unter allergologischer Testung und Therapie.  J Dtsch Dermatol Ges. 2007;  5 230-245
• 21 Fischer J, Knaudt B, Caroli U M. et al . Originalverpackt und abgelaufen – über Notfallsets bei Insektengiftallergie.  J Dtsch Dermatol Ges. 2008;  6 729-733
• 22 Schlegel C, Fux R, Biedermann T. Über die Verwendung von inhalierbarem Adrenalin im Notfallset bei Patienten mit Allergien vom Soforttyp.  J Dtsch Dermatol Ges. 2008;  in Druck
• 23 Shaver K J, Adams C, Weiss S J. Acute myocardial infarction after administration of low-dose intravenous epinephrine for anaphylaxis.  CJEM. 2006;  8 289-294
• 24 Schintler M V, Arbab E, Aberer W. et al . Accidental perforating bone injury using the EpiPen autoinjection device.  Allergy. 2005;  60 259-260
• 25 Oelkers W. Systemische Reaktionen auf Wespenstiche unter ACE-Hemmer Therapie.  Azneimittelbrief. 1994;  28 39-40
• 26 Foody J M, Farrell M H, Krumholz H M. beta-Blocker therapy in heart failure: scientific review.  JAMA. 2002;  287 883-889
• 27 Freemantle N, Cleland J, Young P. et al . beta Blockade after myocardial infarction: systematic review and meta regression analysis.  BMJ. 1999;  318 1730-1737
• 28 Muller U R, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy.  J Allergy Clin Immunol. 2005;  115 606-610
• 29 Laurent J, Smiejan J M, Bloch-Morot E. et al . Safety of Hymenoptera venom rush immunotherapy.  Allergy. 1997;  52 94-96
• 30 Lee Z L, Chang C H, Yang W E. et al . Rush pin fixation versus traction and casting for femoral fracture in children older than seven years.  Chang Gung Med J. 2005;  28 9-15
• 31 Schiavino D, Nucera E, Pollastrini E. et al . Specific ultrarush desensitization in Hymenoptera venom-allergic patients.  Ann Allergy Asthma Immunol. 2004;  92 409-413
• 32 Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.  Allergy. 2000;  55 484-488
• 33 Wenzel J, Meissner-Kraemer M, Bauer R. et al . Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.  Allergy. 2003;  58 1176-1179
• 34 Przybilla B, Ring J, Griesshammer B. et al . Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy.  Dtsch Med Wochenschr. 1987;  112 416-424
• 35 Brockow K, Kiehn M, Riethmuller C. et al . Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.  J Allergy Clin Immunol. 1997;  100 458-463
• 36 Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.  Allergy. 2007;  62 963-964
• 37 Rerinck H, Rueff F, Przybilla B. Recurrent severe anaphylactic reactions to venom immuntherapy (VIT): omalizumab induces tolerance (abstract).  J Allergy Clin Immunol. 2008;  im Druck
• 38 American Academy of Allergy, Asthma and Immunology . The discontinuation of Hymenoptera venom immunotherapy. Report from the Committee on Insects.  J Allergy Clin Immunol. 1998;  101 573-575
• 39 Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.  J Allergy Clin Immunol. 2001;  108 1027-1032
• 40 Rueff F, Przybilla B, Muller U. et al . The sting challenge test in Hymenoptera venom allergy. Position paper of the Subcommittee on Insect Venom Allergy of the European Academy of Allergology and Clinical Immunology.  Allergy. 1996;  51 216-225
• 41 Muller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients.  J Allergy Clin Immunol. 1991;  87 702-709
• 42 Oude Elberink J N, de Monchy J G, Kors J W, van Doormaal J J, Dubois A E. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis.  J Allergy Clin Immunol. 1997;  99 (1 Pt 1) 153-154
• 43 Coombs R RA, Gell P GH. The classification of allergic reactions underlying disease. In: Gell PGH, Coombs RRA (Hrsg) Clinical aspects of immunology. Philadelphia; Davis 1963: